Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications CNS cancer; Lymphoma; Neuroblastoma; Solid tumours
- Focus Therapeutic Use
- Acronyms A Pediatric MATCH Treatment Trial; NCI-COG Pediatric MATCH
- 02 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2020 Status changed from not yet recruiting to recruiting.
- 16 Mar 2020 Planned initiation date changed from 30 Mar 2020 to 6 Sep 2020.